FOURIER is the first large dedicated CV outcomes trial with a PCSK9 inhibitor and examined whether the addition of evolocumab to statin therapy over several years reduces MACE in patients with clinically evident atherosclerotic CVD.

Keywords: ACC17, ACC Annual Scientific Session, Angina, Unstable, Antibodies, Monoclonal, Cholesterol, Cholesterol, LDL, Hospitalization, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipoproteins, Myocardial Infarction, Peripheral Arterial Disease, Proprotein Convertases, Primary Prevention, Stroke, Subtilisins

< Back to Listings